These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 33461346)

  • 1. Erythropoietin promoter polymorphism is associated with treatment efficacy and severe hematologic toxicity for platinum-based chemotherapy.
    Zheng Y; Deng Z; Tang M; Cai P
    Expert Opin Drug Metab Toxicol; 2021 Apr; 17(4):495-502. PubMed ID: 33461346
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel association between CD74 polymorphisms and hematologic toxicity in patients with NSCLC after platinum-based chemotherapy.
    Tan X; Wu Q; Cai Y; Zhao X; Wang S; Gao Z; Yang Y; Li X; Qian J; Wang J; Su B; Chen H; Han B; Jiang G; Lu D
    Clin Lung Cancer; 2014 Jan; 15(1):67-78.e12. PubMed ID: 24220096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients.
    Qian CY; Zheng Y; Wang Y; Chen J; Liu JY; Zhou HH; Yin JY; Liu ZQ
    Chin J Cancer; 2016 Sep; 35(1):85. PubMed ID: 27590272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix metalloproteinase-2 polymorphisms and clinical outcome of Chinese patients with nonsmall cell lung cancer treated with first-line, platinum-based chemotherapy.
    Zhao X; Wang X; Wu W; Gao Z; Wu J; Garfield DH; Wang H; Wang J; Qian J; Li H; Jin L; Li Q; Han B; Lu D; Bai C
    Cancer; 2012 Jul; 118(14):3587-98. PubMed ID: 22072145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The functional polymorphism of erythropoietin gene rs1617640 G>T is not associated with susceptibility and clinical outcome of early-stage breast cancer.
    Szkandera J; Absenger G; Stotz M; Weissmueller M; Winder T; Langsenlehner T; Samonigg H; Renner W; Schippinger W; Gerger A
    Anticancer Res; 2012 Aug; 32(8):3473-8. PubMed ID: 22843933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between CASP8 and CASP10 polymorphisms and toxicity outcomes with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer.
    Qian J; Qu HQ; Yang L; Yin M; Wang Q; Gu S; Wu Q; Zhao X; Wu W; Wu J; Tan X; Chen W; Wang H; Wang J; Fan W; Chen H; Han B; Lu D; Wei Q; Jin L
    Oncologist; 2012; 17(12):1551-61. PubMed ID: 22843554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAD18 polymorphisms are associated with platinum-based chemotherapy toxicity in Chinese patients with non-small cell lung cancer.
    Chu TQ; Li R; Shao MH; Ye JY; Han BH
    Acta Pharmacol Sin; 2016 Nov; 37(11):1490-1498. PubMed ID: 27665847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relation between renal dysfunction requiring renal replacement therapy and promoter polymorphism of the erythropoietin gene in cardiac surgery.
    Popov AF; Schulz EG; Schmitto JD; Coskun KO; Tzvetkov MV; Kazmaier S; Zimmermann J; Schöndube FA; Quintel M; Hinz J
    Artif Organs; 2010 Nov; 34(11):961-8. PubMed ID: 21092038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome.
    Ma W; Kantarjian H; Zhang K; Zhang X; Wang X; Chen C; Donahue AC; Zhang Z; Yeh CH; O'Brien S; Garcia-Manero G; Caporaso N; Landgren O; Albitar M
    BMC Med Genet; 2010 Nov; 11():163. PubMed ID: 21078205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABCB1 c.3435C>T polymorphism is associated with platinum toxicity: a preliminary study.
    De Troia B; Dalu D; Filipazzi V; Isabella L; Tosca N; Ferrario S; Gambaro AR; Somma L; Fasola C; Cheli S; Clementi E; De Francesco D; Falvella FS; Cattaneo MT
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):803-808. PubMed ID: 30796464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-related common miRNA polymorphism associated with severe toxicity in lung cancer patients treated with platinum-based chemotherapy.
    Fang C; Li XP; Gong WJ; Wu NY; Tang J; Yin JY; Li X; Zhang W; Zhou HH; Liu ZQ
    Clin Exp Pharmacol Physiol; 2017 Dec; 44 Suppl 1():21-29. PubMed ID: 27873337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study with vinorelbine, gemcitabine and cisplatin in the treatment of patients with stage IIIb-IV non-small cell lung cancer (NSCLC).
    Ginopoulos P; Mastronikolis NS; Giannios J; Karana A; Siabi V; Karvelas F; Rathossis S; Apostolopoulos N; Mastorakou A
    Lung Cancer; 1999 Jan; 23(1):31-7. PubMed ID: 10100144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythropoietin rs1617640 G allele associates with an attenuated rise of serum erythropoietin and a marked decline of hemoglobin in hepatitis C patients undergoing antiviral therapy.
    Amanzada A; Goralczyk AD; Reinhardt L; Moriconi F; Cameron S; Mihm S
    BMC Infect Dis; 2014 Sep; 14():503. PubMed ID: 25227310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association between COX-2 polymorphisms and hematologic toxicity in patients with advanced non-small-cell lung cancer treated with platinum-based chemotherapy.
    Zhou F; Gao G; Ren S; Li X; He Y; Zhou C
    PLoS One; 2013; 8(4):e61585. PubMed ID: 23620771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients.
    Wu W; Li H; Wang H; Zhao X; Gao Z; Qiao R; Zhang W; Qian J; Wang J; Chen H; Wei Q; Han B; Lu D
    PLoS One; 2012; 7(3):e33200. PubMed ID: 22479369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of functional LIG4 polymorphism on platinum-based chemotherapy response and survival in non-small cell lung cancer.
    Jiang YH; Xu XL; Ruan HH; Xu WZ; Li D; Feng JG; Han QB; Mao WM
    Med Oncol; 2014 May; 31(5):959. PubMed ID: 24722796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of GSTP1 and RRM1 Polymorphisms with the Response and Toxicity of Gemcitabine-cisplatin Combination Chemotherapy in Chinese Patients with Non-small Cell Lung Cancer.
    Yuan ZJ; Zhou WW; Liu W; Wu BP; Zhao J; Wu W; He Y; Yang S; Su J; Luo Y
    Asian Pac J Cancer Prev; 2015; 16(10):4347-51. PubMed ID: 26028097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, toxicity and cost analysis for non-platinum triplet (gemcitabine and vinorelbine, followed by docetaxel) vs. platinum-based chemotherapy in IIIB/IV non-small-cell lung cancer: single-institution experience.
    Tada H; Matsui S; Kawahara M; Hosoe S; Hamada C; Fukushima M
    Eur J Cancer Care (Engl); 2008 Mar; 17(2):120-6. PubMed ID: 18302648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytidine deaminase 435C>T polymorphism relates to gemcitabine-platinum efficacy and hematological toxicity in Chinese non-small-cell lung cancer patients.
    Hu L; Mao X; Gao C; Xu Y; Li C; Wang T; Lv D
    Neoplasma; 2021 May; 68(3):638-644. PubMed ID: 33724861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. XBP1 promoter polymorphism modulates platinum-based chemotherapy gastrointestinal toxicity for advanced non-small cell lung cancer patients.
    Peng J; Chen YY; Yang LX; Zhao XY; Gao ZQ; Yang J; Wu WT; Wang HJ; Wang JC; Qian J; Chen HY; Jin L; Bai CX; Han BH; Lu DR
    Lung Cancer; 2013 Jun; 80(3):333-8. PubMed ID: 23510626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.